Leukemia | Norton Healthcare

Indication: Leukemia

A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination with Azacitidine and/or Venetoclax in Subjects with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Sub-indication: Hematological Malignancies

Study Type: Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Sponsor: AbbVie

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.